Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids

Endocrine-Related Cancer

Volumn 17, Issue 3, 2010, Pages 719-729

  Zatelli, Maria Chiara ^a   Minoia, Mariella ^a   Martini, Chiara ^b   Tagliati, Federico ^a   Ambrosio, Maria Rosaria ^a   Schiavon, Marco ^b   Buratto, Mattia ^a   Calabrese, Fiorella ^b   Gentilin, Erica ^a   Cavallesco, Giorgio ^a   Berdondini, Lisa ^a   Rea, Federico ^b   Degli Uberti, Ettore C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PASIREOTIDE; PROTEIN KINASE B; S6 KINASE; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRONCHUS CARCINOID; CELL VIABILITY; CLINICAL ARTICLE; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION;

ADULT; AGED; BLOTTING, WESTERN; BRONCHIAL NEOPLASMS; CARCINOID TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956391941     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0097     Document Type: Article

References (36)

1. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M et al. 2010 The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9 1781-1791.
2. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Khan MA, Jones RT & Harris CC 1998 Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. British Journal of Cancer 78 233-239. (Pubitemid 28302262)
3. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP, Colby TV, Sheppard M, Shimosato Y, Koss MN et al. 2000 Pulmonary atypical carcinoid: predictors of survival in 106 cases. Human Pathology 31 1255-1265.
4. Bertino EM, Confer PD, Colonna JE, Ross P & Otterson GA 2009 Pulmonary neuroendocrine/carcinoid tumors: a review article. Cancer 115 4434-4441.
5. Bjornsti M-A & Houghton PJ 2004 The TOR pathway: a target for cancer therapy. Nature Reviews. Cancer 4 335-348. (Pubitemid 38579480)
6. Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa'y L & degli Uberti EC 2005 Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy. World Journal of Gastroenterology 11 2041-2044.
7. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 146 707-716. (Pubitemid 34552506)
8. Chelly J, Concordet JP, Kaplan JC & Kahn A 1989 Illegitimate transcription: transcription of any gene in any cell type. PNAS 86 2617-2621. (Pubitemid 19112598)
9. Das-Neves-Pereira JC, Bagan P, Milanez-de-Campos JR, Capelozzi VL, Danel C, Jatene FB, Bernaudin JF & Riquet M 2008 Individual risk prediction of nodal and distant metastasis for patients with typical bronchial carcinoid tumors. European Journal of Cardio-Thoracic Surgery 34 473-478.
10. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G & Rena O 2002 Long-term serviva of atypical bronchial carcinoids with liver metastases, treated with octreotide. European Journal of Cardio-Thoracic Surgery 21 913-917. (Pubitemid 34308953)
11. Fonsatti E & Maio M 2004 Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. Journal of Translational Medicine 2 18.
12. Fonsatti E, Altomonte M, Nicotra MR, Natali PG & Maio M 2003 Endoglin (CD105): a powerful therapeutic target on tumorassociated angiogenetic blood vessels. Oncogene 22 6557-6563.
13. Granberg D, Wilander E & Oberg K 2006 Expression of tyrosine kinase receptors in lung carcinoids. Tumour Biology 27 153-157.
14. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, Salahuddin N, Korbonits M & Grossman AB 2008 Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 87 168-181.
15. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV & Modlin IM 2008 Bronchopulmonary neuroendocrine tumors. Cancer 113 5-21.
16. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K & Grossman AB 2001 The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 86 881-887. (Pubitemid 32207510)
17. Mabasa VH & Ensom MH 2005 The role of therapeutic monitoring of everolimus in solid organ transplantation. Therapeutic Drug Monitoring 27 666-676.
18. Oberg K & Jelic S 2009 ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Annals of Oncology 20 (Suppl 4) 147-149.
19. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al. 2006 MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66 1500-1508. (Pubitemid 43259931)
20. Pollak MN, Polychronakos C & Guyda H 1989 Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Research 9 889-891.
21. Raica M, Cimpean AM & Ribatti D 2009 Angiogenesis in pre-malignant conditions. European Journal of Cancer 45 1924-1934.
22. Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G & Papotti M 2010 Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Annals of Oncology 21 548-555.
23. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663.
24. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P & Anthony L 1999 Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology 17 600-606. (Pubitemid 29075248)
25. Srirajaskanthan R, Toumpanakis C, Karpathakis A, Marelli L, Quigley AM, Dusmet M, Meyer T & Caplin ME 2009 Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung Cancer 65 68-73.
26. Tagliati F, Zatelli MC, Bottoni A, Piccin D, Luchin A, Culler MD & degli Uberti EC 2006 Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro. Endocrinology 147 3530-3538. (Pubitemid 43901144)
27. Travis W & Brambilla E 2004 Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon: IARC Press.
28. Wulbrand U, Remmert G, Zofel P, Wied M, Arnold R & Fehmann HC 2000 mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. European Journal of Clinical Investigation 30 729-739. (Pubitemid 30604075)
29. Yao JC 2007 Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Practice & Research. Clinical Endocrinology & Metabolism 21 163-172.
30. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A et al. 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology 26 4311-4318.
31. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69-76.
32. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L et al. 2004 Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 89 5181-5188.
33. Zatelli MC, Maffei P, Piccin D, Martini C, Rea F, Rubello D, Margutti A, Culler MD, Sicolo N & degli Uberti EC 2005 Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. Journal of Clinical Endocrinology and Metabolism 90 2104-2109.
34. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M et al. 2007 Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocrine-Related Cancer 14 91-102.
35. Zatelli MC, Minoia M, Molè D, Cason V, Tagliati F, Margutti A, Bondanelli M, Ambrosio MR & degli Uberti E 2009 Growth hormone excess promotes breast cancer chemoresistance. Journal of Clinical Endocrinology and Metabolism 94 3931-3938.
36. Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M & degli Uberti EC 2010 Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 95 968-976.